Background
==========

Obstructive sleep apnea-hypopnea syndrome (OSAS) is a clinical syndrome that involves repeated episodes of obstruction of the upper airway, which are accompanied by apnea/hypopnea and sleep interruption. OSAS is a public health concern in modern society. The incidence of OSAS in males is higher than in females. The ratio of males to females with OSAS is reported to be between 3: 1 and 5: 1. However, other studies have reported a ratio as high as 10: 1 \[[@b1-medscimonit-25-3558], [@b2-medscimonit-25-3558]\].

Studies have shown that the incidence of OSAS in diabetic patients is up to 23% \[[@b3-medscimonit-25-3558]\]. Eihorn et al. \[[@b4-medscimonit-25-3558]\] found that approximately 48% of a diabetic population had apnea-hypopnea index \>10/h. Recent evidence has suggested a link between type 2 diabetes mellitus (T2DM) and OSAS, due to factors including obesity, inflammation, and oxidative stress.

Carcinoembryonic antigen (CEA) is a highly glycosylated cell surface glycoprotein that is used as a tumor marker. The CEA level is abnormally elevated in patients with colorectal cancer. Recently, CEA was reported to be significantly elevated in patients with metabolic diseases such as T2DM \[[@b5-medscimonit-25-3558]\]. Moreover, Nieto, whose study included 1522 investigators and was based on the community Wisconsin Sleep Cohort Study found there was a dose-response relationship between OSAS and cancer mortality, which was more significant in severely hypoxic patients \[[@b6-medscimonit-25-3558]\]. The pro-oncogenic properties of the hypoxia caused by OSAS have been demonstrated by *in vitro* studies \[[@b7-medscimonit-25-3558]\]. Chen Wen-Jone found increased levels of CEA in hypoxic-treated animal models \[[@b8-medscimonit-25-3558]\]. Kokkonen et al. found that hypoxia-inducible factor 1α (HIF-1α), which was recognized as a hypoxia marker, can enhance CEA promoter activity and up-regulate CEA expression in an anoxic environment \[[@b9-medscimonit-25-3558]\]. However, to the best of our knowledge, this is the first report on the association between OSAS and the CEA level in patients with T2DM. This study focused on the link between OSAS and serum CEA levels in T2DM patients.

Material and Methods
====================

Subjects
--------

Our study enrolled a total of 401 participants age 21--91 years diagnosed with T2DM, who were hospitalized at the Department of Endocrinology, Changzhou First People's Hospital from 2011 to 2016, including 244 patients with OSAS and 157 patients without OSAS. The exclusion criteria were \[[@b10-medscimonit-25-3558]\]: diabetic ketoacidosis, diabetic nonketotic hyperosmolar coma, acute cardiovascular diseases, acute cerebrovascular diseases, acute infection, malignant disease, chronic liver disease, and subjects taking psychotropic drugs or who had surgery, trauma, or burns in the past 6 months. Approval from the local ethics committee of the Third Affiliated Hospital of Suzhou University was obtained.

Diagnostic criteria for T2DM and OSAS
-------------------------------------

All T2DM patients met the 1999 WHO diagnostic criteria for diabetes. The diagnostic criteria for OSAS were the guidelines for the diagnosis and treatment of OSAS developed by the Chinese Medical Association Respiratory Branch Sleep Disorders Group \[[@b11-medscimonit-25-3558]\].

Clinical and laboratory evaluation
----------------------------------

The body mass index (BMI) was calculated by the formula body weight (kg)/height (m)^2^. Data on height, weight, blood pressure, cigarette-smoking habits, and alcohol consumption were collected for all patients.

We measured the serum levels of fasting blood glucose (FPG), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), alanine aminotransferase (ALT), creatinine (Cr), C-reactive protein (CRP), glycosylated hemoglobin (HbA1c), fasting c-peptide (FCP), and carcinoembryonic antigen (CEA). The normal range of CEA was 0--5 ng/mL.

Overnight polysomnography (PSG) monitoring was performed using a Somnostar 4000 model (Sensor Medics, Inc., USA) and a Sandman polysomnography system. The apnea-hypopnea index (AHI) and oxygen desaturation index (ODI) were recorded with the PSG monitoring indicator.

Statistical methods
-------------------

SPSS version 22 (SPSS, Inc., Chicago, IL, USA) was used for the statistical analysis. All measurement data were represented by the average ± standard deviation or the median (interquartile range). Normally distributed data were compared with *t* tests; otherwise, the data were analyzed by the Mann-Whitney U test. The proportions were expressed as% (n) and compared by chi-square tests. Correlations between different variables were analyzed by the Pearson or Spearman tests. Binary logistic regression and multiple linear regression analyses were performed to further determine the degree of correlation between OSAS and CEA level in T2DM patients. *P*\<0.05 was considered statistically significant. The graphs were constructed using GraphPad Prism 6.0.

Results
=======

Clinical characteristics of the T2DM subjects with and without OSAS
-------------------------------------------------------------------

The baseline characteristics of the study population are shown in [Table 1](#t1-medscimonit-25-3558){ref-type="table"}. There were 244 T2DM patients with OSAS and 157 T2DM patients without OSAS. Compared with those without OSAS, there were more male patients with OSAS. Furthermore, compared with those without OSAS, the patients with OSAS had higher levels of alcohol consumption, CEA, DBP, BMI, ALT, CRP, and FCP and lower levels of HDL-C (*p*\<0.05). We further divided the patients into 2 groups according to AHI score, as follows: mild-to-moderate OSAS (5≤ AHI \<30) and severe OSAS (AHI ≥30). As shown in [Figure 1](#f1-medscimonit-25-3558){ref-type="fig"}, the serum CEA level in the severe OSAS group was significantly higher than that in the mild-to-moderate OSAS group (*p*\<0.05).

Relationship between OSAS and the CEA level
-------------------------------------------

We analyzed the correlations between the CEA level and other variables ([Table 2](#t2-medscimonit-25-3558){ref-type="table"}). The results indicated that the level of serum CEA was related to male sex and smoking. Simultaneously, the level of CEA was positively correlated with AHI, ODI, FBG, and HbA1c (*p*\<0.05).

The results of the logistic regression analysis in T2DM patients are listed in [Table 3](#t3-medscimonit-25-3558){ref-type="table"}. When confounding factors were not adjusted in the model, the AHI score was an independent risk factor for increased CEA levels (OR=1.021, 95% CI: 1.008--1.034, *p*=0.002). After adjusting for age, gender, duration of T2DM, current smoking, current alcohol consumption, SBP, DBP, BMI, CRP, HbA1c, TC, TG, LDL-C, HDL-C, FBG, FCP, ALT, and Cr, the AHI score remained associated with the CEA level (OR=1.052, 95% CI: 1.011\~1.095*, p*=0.013). Similar results were also observed in the relationship between ODI and CEA after adjusting for other variables (OR=1.214, 95% CI: 1.070\~1.377*, p*=0.003).

Levels of CEA in different subgroups
------------------------------------

We further divided the participants into different subgroups according to the clinical characteristics that were investigated, as shown in [Figure 2](#f2-medscimonit-25-3558){ref-type="fig"}. The results indicated that in men, patients age \<54 years, patients with T2DM duration \<36 months, current smokers, patients who do not consume alcohol, patients with BMIs ≥28 kg/m^2^, patients with HbA1c levels ≥7%, and patients with LDL-C levels ≥2.3 mmol/l, those with OSAS had higher levels of CEA than those without OSAS (*p*\<0.05).

Furthermore, we analyzed the interactions between the confounders such as age, sex, lifestyle factors, T2DM duration, obesity, the status of glucose control, and other metabolism-related factors and levels of AHI to the risk of increased CEA, the negative results were found(*p*\>0.05). The results of the multiple linear regression analysis are shown in the scatter plots in [Figure 3](#f3-medscimonit-25-3558){ref-type="fig"}. The results revealed the AHI was positively linearly correlated with the level of CEA in men, smokers, patients with BMIs ≥28 kg/m^2^ and patients with HbA1c levels ≥7%, with coefficients of 0.027, 0.049, 0.025 and 0.022, respectively (*p*\<0.05). Similar results were also observed in the relationship between ODI and CEA, with coefficients of 0.022, 0.043, 0.024, and 0.022, respectively (*p*\<0.05)

Discussion
==========

The CEA level is commonly used as an early tumor screening index. Recent studies have found that the level of CEA is elevated in other diseases, such as liver disease, kidney dysfunction, hypothyroidism, and acute/chronic infectious diseases. Kyu-Nam Kim \[[@b12-medscimonit-25-3558]\] reported that increased CEA levels are found in metabolic diseases such as diabetes. Simultaneously, a relationship between OSAS and cancer has been reported in recent years \[[@b10-medscimonit-25-3558],[@b13-medscimonit-25-3558]\]. However, there have been few studies about CEA levels in patients with diabetes with OSAS.

The results of this study demonstrate that patients with T2DM and OSAS had significantly higher CEA levels than T2DM patients without OSAS, and those higher levels were associated with sex, obesity, smoking, and poor glycemic control.

Therefore, we believed that there was a relationship between OSAS and the serum CEA levels in T2DM patients, and hypoxemia might be the possible mechanism. Kent reported \[[@b14-medscimonit-25-3558]\] that hypoxemia caused by OSAS can promote insulin resistance and obesity in T2DM patients by aggravating the inflammatory response, activating oxidative stress, and aggravating glucose metabolism disorders, and all of these may play an important role in the link between OSAS and serum CEA levels in T2DM patients. Insulin produces mitogenic effects that affect the growth of epithelial cells via insulin-like growth factor-1 (IGF-1) \[[@b15-medscimonit-25-3558]\]. Zhang et al. \[[@b16-medscimonit-25-3558]\] reported that blocking the corresponding IGF sequence with the antisense IGF-I gene can reduce serum CEA levels. Therefore, insulin resistance may be associated with an increase in CEA levels.

Most OSAS patients are obese. Clinical studies have shown that tumors are associated with diet and weight gain \[[@b17-medscimonit-25-3558]\]. Obesity promotes the secretion of insulin and IGF-1 to promote the survival and production of tumor cells \[[@b18-medscimonit-25-3558]\]. Through weight loss and gastric volume reduction surgery, the incidence of cancer can be reduced and the quality of life can be improved \[[@b19-medscimonit-25-3558]\]. The study by Almendros et al. on tumors in OSAS patients in 2012 showed that obesity can increase tumor growth independent of hypoxemia \[[@b20-medscimonit-25-3558]\]. Second, visceral fat accumulation is associated with insulin resistance and obesity in T2DM patients. Visceral fat releases a greater number of adipokines that are associated with cancer \[[@b21-medscimonit-25-3558]\]. Lee et al. found that CEA is associated with visceral fat area and is considered as a mediator that links metabolic disorders and tumorigenesis in patients with visceral obesity \[[@b22-medscimonit-25-3558]\].

Inflammation is a characteristic response of tumors. Inflammatory cells, inflammatory chemokines, and cytokines regulate the growth, metastasis, and differentiation of tumors \[[@b23-medscimonit-25-3558]\]. The mechanisms include the production of auxin, the promotion of angiogenesis, inducing DNA damage, altering extracellular matrix components, and escaping host immune defenses by coating tumor cells \[[@b24-medscimonit-25-3558]\]. Kim et al. reported the components of metabolic syndrome are positively correlated with the CEA level and considered CEA as a tumor marker that was simultaneously associated with chronic inflammation \[[@b12-medscimonit-25-3558]\].

Oxidative stress that plays an important role in OSAS \[[@b25-medscimonit-25-3558]\], and diabetes \[[@b26-medscimonit-25-3558]\] is one of the main drivers of cancer development \[[@b27-medscimonit-25-3558]\]. The onset of cancer is regulated by high levels of reactive oxygen species, triggering DNA mutations that affect the transmission of oncogene signaling and leading to the development of aggressive cancer \[[@b27-medscimonit-25-3558]\]. Hasan et al. reported that in diabetes patients, CEA is positively correlated with malondialdehyde (MDA), which is a known oxidative stress marker \[[@b28-medscimonit-25-3558]\].

Conclusions
===========

In summary, this study suggests that T2DM patients who have OSAS are prone to abnormal increases in serum CEA levels. We should consider the effects of metabolic disorders on CEA levels. As CEA is an indicator that is sensitive to tumor prediction, we think the risk of tumor development in T2DM patients with OSAS will increase significantly in the future. Further research is needed to confirm our findings.
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###### 

Comparison of the clinical characteristics of the T2DM patients with and without OSAS.

  Variables                         T2DM with OSAS (n=244)    T2DM without OSAS (n=157)   *p* Value
  --------------------------------- ------------------------- --------------------------- -----------
  Sex (Male/Female)                 203/41                    110/47                      0.002
  Age (years)                       54.00 (46.00--63.00)      52.00 (42.50--61.50)        0.158
  Duration of T2DM (months)         36.00 (2.00--108.00)      36.00 (6.00--84.00)         0.900
  Current smoker (%)                93 (38.11)                46 (29.30)                  0.070
  Current alcohol consumption (%)   82 (33.61)                36 (22.93)                  0.022
  CEA (ng/mL)                       2.54 (1.83--3.22)         2.24 (1.71--3.05)           0.035
  SBP (mmHg)                        138.00 (127.00--153.00)   134.50 (127.00--147.00)     0.110
  DBP (mmHg)                        85.00 (78.00--92.00)      82.00 (76.00--90.00)        0.015
  BMI (kg/m2)                       28.09 (25.87--30.08)      25.20 (23.24--26.97)        0.000
  CRP (mg/L)                        4.05 (3.50--5.50)         3.80 (3.50--4.20)           0.012
  FBG (mmol/L)                      8.69 (7.26--11.03)        8.70 (7.00--10.40)          0.429
  FCP (ng/mL)                       2.22 (1.73--3.04)         1.88 (1.49--2.63)           0.002
  HbA1c (%)                         8.70 (7.50--10.30)        9.10 (7.55--10.50)          0.379
  TG (mmol/L)                       3.07 (1.98--4.88)         3.04 (1.84--4.59)           0.575
  TC (mmol/L)                       4.56 (3.73--5.17)         4.60 (3.97--5.29)           0.242
  LDL-C (mmol/L)                    2.29±0.04                 2.26±0.06                   0.677
  HDL-C (mmol/L)                    0.90 (0.80--1.05)         0.97 (0.84--1.13)           0.002
  Cr (μmol/L)                       73.00 (63.00--86.90)      71.65 (62.18--84.85)        0.341
  ALT (u/L)                         27.00 (20.00--46.00)      25.00 (18.00--32.00)        0.019

Data were expressed as % (n), mean ± standard deviation and median (interquartile range). SBP -- systolic blood pressure; DBP -- diastolic blood pressure; BMI -- body mass index; FBG -- fasting blood glucose; TC -- total cholesterol; TG -- triglyceride; LDL-C -- low-density lipoprotein cholesterol; HDL-C -- high-density lipoprotein cholesterol; ALT -- alanine aminotransferase; Cr -- creatinine; CRP -- C-reactive protein; HbA1c -- glycosylated hemoglobin; FCP -- fasting c-peptide; CEA -- carcinoembryonic antigen.

###### 

Correlation analysis between serum CEA levels and other selected variables.

  Variables                     Pearson's coefficient   *p* Value
  ----------------------------- ----------------------- -----------
  Duration of T2DM              −0.034                  0.548
  Age                           0.047                   0.383
  Sex                           0.200                   0.000
  Current smoking               0.156                   0.004
  Current alcohol consumption   0.032                   0.564
  AHI                           0.242                   0.000
  ODI                           0.155                   0.013
  BMI                           0.065                   0.230
  SBP                           0.018                   0.736
  DBP                           0.048                   0.377
  FBG                           0.133                   0.015
  HbA1c                         0.138                   0.011
  FCP                           0.050                   0.402
  ALT                           0.005                   0.928
  Cr                            0.054                   0.385
  CRP                           −0.052                  0.447
  TG                            0.073                   0.183
  TC                            −0.041                  0.458
  HDL-C                         −0.079                  0.155
  LDL-C                         0.000                   0.996

SBP -- systolic blood pressure; DBP -- diastolic blood pressure; BMI -- body mass index; FBG -- fasting blood glucose; TC -- total cholesterol; TG -- triglyceride; LDL-C -- low-density lipoprotein cholesterol; HDL-C -- high-density lipoprotein cholesterol; ALT -- alanine aminotransferase; AHI -- apnea-hypopnea index; ODI -- oxygen desaturation index; Cr -- creatinine; CRP -- C-reactive protein; HbA1c -- glycosylated hemoglobin; FCP -- fasting c-peptide; CEA -- carcinoembryonic antigen.

###### 

Logistic regression analysis of the median CEA in T2DM patients.

                    OR               (95% CI)         *P* value
  --------- ------- ---------------- ---------------- -----------
  Model 1   AHI     1.021            (1.008--1.034)   0.002
  ODI       1.017   (1.004--1.030)   0.012            
  Model 2   AHI     1.02             (1.005--1.035)   0.008
  ODI       1.017   (1.002--1.034)   0.031            
  Model 3   AHI     1.052            (1.011--1.095)   0.013
  ODI       1.214   (1.070--1.377)   0.003            

Model 1 was not adjusted. Model 2 was adjusted for age, sex, T2DM duration, current smoking, and current alcohol consumption. Model 3 was adjusted for age, sex, T2DM duration, current smoking, current alcohol consumption, systolic blood pressure, diastolic blood pressure, body mass index, and the levels of C-reactive protein, hemoglobin A1c, total cholesterol, triacylglycerol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting blood glucose, fasting c-peptide, alanine aminotransferase, and creatinine. OR -- odds ratio; CI -- confidence interval; AHI -- apnea-hypopnea index; ODI -- oxygen desaturation index; CEA -- carcinoembryonic antigen.
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